Italian rehabilitation robotics startup Wearable Robotics has secured €5 million in Series A funding to accelerate the global expansion of its innovative arm exoskeleton technology. The company, which originated from the prestigious Sant’Anna School of Advanced Studies in Pisa, has been making waves in the medical rehabilitation sector since its founding in 2014.
Global Reach and Investment Backing
The ALEX RS bilateral upper-limb exoskeleton developed by Wearable Robotics has already been deployed across 20 countries, establishing the company as a key player in the field of assistive robotics. The funding round was led by CDP Venture Capital, with additional support from SIMEST, an Italian organization that provides funding for international expansion through Italy’s Ministry of Foreign Affairs. This investment underscores the growing interest in rehabilitation technology and the potential for such innovations to transform patient care globally.
Advancing Rehabilitation Through Robotics
Wearable Robotics’ exoskeleton is designed to support individuals recovering from stroke or spinal cord injuries by assisting with upper-limb movement and rehabilitation exercises. The company's technology not only enhances the recovery process but also offers a scalable solution for rehabilitation centers worldwide. With this new funding, the startup aims to expand its manufacturing capabilities and strengthen its presence in key markets, particularly in North America and Asia.
The company’s success reflects a broader trend in the healthcare industry, where robotics and AI are increasingly being integrated into treatment protocols. As demand for more effective and accessible rehabilitation tools continues to rise, Wearable Robotics is well-positioned to lead the charge in this rapidly evolving field.
Looking Ahead
With the new capital, Wearable Robotics is expected to accelerate product development, enhance user experience, and explore partnerships with hospitals and clinics. As the global market for rehabilitation robotics is projected to grow significantly in the coming years, this funding round could be a pivotal moment for the company’s international expansion and long-term impact in improving patient outcomes.
